Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

Lalitha Shankar(National Institutes of Health), John M. Hoffman(Huntsman Cancer Institute), S.L. Bacharach(University of California, San Francisco), Michael M. Graham(University of Iowa), Joel S. Karp, Adriaan A. Lammertsma(Vrije Universiteit Amsterdam), Steven M. Larson(Memorial Sloan Kettering Cancer Center), David A. Mankoff(University of Washington), Barry A. Siegel(Mallinckrodt (Ireland)), Annick Van den Abbeele(Harvard University Press), Jeffrey T. Yap(Harvard University Press), Daniel M. Sullivan(National Institutes of Health),
PubMed
June 1, 2006
Cited by 679

Abstract

Many therapeutic clinical trials have proposed using a measure of metabolic change to assess therapeutic response rather than relying on conventional anatomic measurements of changes in tumor size on CT or MRI. PET assessment of changes in 18F-FDG uptake by tumors is gaining accep-tance as such a measure. Despite the increasing use of 18F-FDG PET as a bio-marker for predicting therapeutic response, there are no widely accepted standardized protocols for using 18F-FDG PET as a tool for assessing response to therapy, nor are there validated criteria for judging response using 18F-FDG PET. The European PET community, working with the European Organization for Research and Treatment of Can-cer, initiated a project to begin defining response criteria for PET and published their preliminary consensus recommen-

Related Papers

No related papers found

Powered by citation graph analysis